翰森制药：HS-10365胶囊上市许可申请获国家药品监督管理局受理

Core Viewpoint - Hansoh Pharmaceutical (03692) announced that its innovative drug HS-10365, a highly selective translocation inhibitor, has received acceptance for its New Drug Application (NDA) by the National Medical Products Administration (NMPA) of China on October 23, 2025, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with RET gene fusion [1] Group 1 - The drug HS-10365 is specifically designed for patients with RET gene fusion positive NSCLC [1] - The acceptance of the NDA marks a significant step in the drug's development and potential market entry [1] - This development highlights the company's focus on innovative treatments in oncology [1]